US · Healthcare · Biotechnology
EPS came in at -0.83 against a street estimate of -0.78 — a miss of 6.4%.
Analysts rate Scholar Rock Holding Corp a strong buy (10 buy, 0 hold, 0 sell out of 10) with an average price target of $59.31.
| Fund | Stake |
|---|---|
| FMR Inc | 14.39% |
| Siren, L.L.C. | 9.03% |
| Redmile Group, LLC | 7.57% |
| BlackRock Inc | 6.23% |
| Samsara BioCapital, LLC | 5.76% |
| Wellington Management Company LLP | 5.61% |
| T. Rowe Price Associates, Inc. | 5.18% |
| Orbis Allan Gray Ltd | 3.49% |
| Document | Date |
|---|---|
| Shareholder vote results · Q2 2026 | 2026-06-05 |
| Quarterly report · Q1 2026 | 2026-05-07 |
| Results announced · Q2 2026 | 2026-05-07 |
| Proxy statement · Q2 2026 | 2026-04-22 |
| Reg FD disclosure · Q1 2026 | 2026-03-31 |
| Annual report FY2025 | 2026-03-03 |
| Results announced · Q1 2026 | 2026-03-03 |
| Quarterly report · Q3 2025 | 2025-11-14 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Scholar Rock Holding Corp — free to start.
Google PlayApp StoreData updated 2026-08-05.